Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective

  title={Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective},
  author={Crystal Jing Jing Yeo and Z. Simmons},
  journal={Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration},
  pages={167 - 172}
  • Crystal Jing Jing Yeo, Z. Simmons
  • Published 2018
  • Psychology, Medicine
  • Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
  • Abstract The recent approval of edaravone by the United States Food and Drug Administration has generated a mix of hope tempered by reality. The costs of the drug, both monetarily and with regard to intensity of treatment, are high. The benefits, while modest, will be viewed through a very different lens by individuals depending on their goals of care. By virtue of our training and experience, physicians are ideally suited to understand and explain new treatments to our patients. As healthcare… CONTINUE READING
    9 Citations

    Topics from this paper

    Paper Mentions

    Palliative care in motor neurone disease: where are we now?
    • 8
    Gamisoyo-San Ameliorates Neuroinflammation in the Spinal Cord of hSOD1G93A Transgenic Mice
    • 2
    • PDF
    Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study
    • 20
    Edaravone in the treatment of amyotrophic lateral sclerosis.
    • 9


    July 2017 ENCALS statement on edaravone
    • 22
    • PDF
    Is quality of life determined by expectations or experience?
    • 735
    • PDF
    Health literacy : a prescription to end confusion
    • 3,557
    • PDF
    Patient-Perceived Outcomes and Quality of Life in ALS
    • 36
    • PDF
    Correlates of suffering in amyotrophic lateral sclerosis
    • 217
    Quality of life in ALS is maintained as physical function declines
    • 99